SCHEMBL8424748

SCHEMBL8424748

Sc1n[nH]c2c(CCNC3CC3)cccc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.40
LMNA P02545 3/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
GAA P10253 1/20 0.38
ALOX12 P18054 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MAPK1 P28482 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
CCNE2 O96020 2/20 0.37
CDK4 P11802 2/20 0.37
PRKACA P17612 2/20 0.37
PRKACG P22612 2/20 0.37
PRKACB P22694 2/20 0.37
CCND1 P24385 2/20 0.37
CCNE1 P24864 2/20 0.37
CDK2 P24941 2/20 0.37
CAMK2B Q13554 2/20 0.37
CAMK2G Q13555 2/20 0.37
CAMK2D Q13557 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8424790 0.80 KDM4E (0.43) ALDH1A1LMNAMEN1KMT2AMAPK1
SCHEMBL3533773 0.77 SLC6A2 (0.49) ALDH1A1LMNAMEN1KMT2AGAA
SCHEMBL8423751 0.74 MPO (0.42) MAPK1SMN1; SMN2HTR2AMAPT
SCHEMBL24822496 0.71 MTNR1A (0.51) ALDH1A1LMNAMEN1KMT2AGAA
SCHEMBL8426598 0.71 HTR6 (0.43) HTR2A
SCHEMBL8426645 0.67 GRIN2B (0.39) LMNASMN1; SMN2GRIN2BCXCR4
SCHEMBL3666001 0.66 SLC18A2 (0.52) ALDH1A1MEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL3571257 0.65 SLC6A2 (0.64) ALDH1A1MEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL28773617 0.65 ALDH1A1 (0.50) ALDH1A1LMNAMEN1KMT2AGAA
SCHEMBL2468664 0.65 ALDH1A1 (0.47) ALDH1A1LMNAMEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7723329-B2 Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands WYETH LLC (US) 2010-05-25 US disclosed
US-20070037802-A1 such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders WYETH (US) 2007-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037802-A1 such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders HTR6, TPH1, HTR1A ALDH1A1 690/4885LMNA 1977/4885MEN1 1034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.